CBIO- Interesting Stock- Why Up?

63 1
Why did CBIO stock shares practically triple? On longer charts,stock worth over $3,000 share once.

Catalyst Biosciences Inc . ( CBIO ) saw its shares practically triple in Tuesday’s session after the company announced a critical regulatory approval. The company reported that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug Application (IND) for CB 2679d/ISU304, which works to treat individuals with hemophilia.

Hemophilia is a serious bleeding disorder that results in spontaneous bleeding episodes, as well as substantially prolonged bleeding times upon injury.

Terms of drug, it is a highly potent next-generation coagulation Factor IX variant, demonstrated potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. In simpler terms, CB2679d/ISU304 works to inhibit blood loss and can be used as a preventative treatment to individuals with hemophilia. * F.Y.I for possible investment in.
This stock had a reverse split that brought its float under 1 million shares (day trader target). When that happened, they had around $12cash/share on hand so it had it's small spike. With news of an actual use for their drug, this was traded big time.
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out